These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 26836949)

  • 1. The role of IL-18 in type 1 diabetic nephropathy: The problem and future treatment.
    Elsherbiny NM; Al-Gayyar MM
    Cytokine; 2016 May; 81():15-22. PubMed ID: 26836949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-18 and diabetic nephropathy: A review.
    Yaribeygi H; Atkin SL; Sahebkar A
    J Cell Physiol; 2019 May; 234(5):5674-5682. PubMed ID: 30417374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy.
    Elmarakby AA; Sullivan JC
    Cardiovasc Ther; 2012 Feb; 30(1):49-59. PubMed ID: 20718759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of IL-20 in chronic kidney disease and diabetic nephropathy: Pathogenic and therapeutic implications.
    Chang MS; Hsu YH
    J Leukoc Biol; 2018 Nov; 104(5):919-923. PubMed ID: 29999545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-18 contributes more closely to the progression of diabetic nephropathy than other diabetic complications.
    Fujita T; Ogihara N; Kamura Y; Satomura A; Fuke Y; Shimizu C; Wada Y; Matsumoto K
    Acta Diabetol; 2012 Apr; 49(2):111-7. PubMed ID: 20186552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetes, inflammation, proinflammatory cytokines, and diabetic nephropathy.
    Navarro JF; Mora C
    ScientificWorldJournal; 2006 Aug; 6():908-17. PubMed ID: 16906324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperuricemia-induced NLRP3 activation of macrophages contributes to the progression of diabetic nephropathy.
    Kim SM; Lee SH; Kim YG; Kim SY; Seo JW; Choi YW; Kim DJ; Jeong KH; Lee TW; Ihm CG; Won KY; Moon JY
    Am J Physiol Renal Physiol; 2015 May; 308(9):F993-F1003. PubMed ID: 25651569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammation and the pathogenesis of diabetic nephropathy.
    Wada J; Makino H
    Clin Sci (Lond); 2013 Feb; 124(3):139-52. PubMed ID: 23075333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Albumin stimulates renal tubular inflammation through an HSP70-TLR4 axis in mice with early diabetic nephropathy.
    Jheng HF; Tsai PJ; Chuang YL; Shen YT; Tai TA; Chen WC; Chou CK; Ho LC; Tang MJ; Lai KT; Sung JM; Tsai YS
    Dis Model Mech; 2015 Oct; 8(10):1311-21. PubMed ID: 26398934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant activation profile of cytokines and mitogen-activated protein kinases in type 2 diabetic patients with nephropathy.
    Wong CK; Ho AW; Tong PC; Yeung CY; Kong AP; Lun SW; Chan JC; Lam CW
    Clin Exp Immunol; 2007 Jul; 149(1):123-31. PubMed ID: 17425653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy.
    Navarro-González JF; Mora-Fernández C; Muros de Fuentes M; García-Pérez J
    Nat Rev Nephrol; 2011 Jun; 7(6):327-40. PubMed ID: 21537349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenic perspectives for the role of inflammation in diabetic nephropathy.
    Rivero A; Mora C; Muros M; García J; Herrera H; Navarro-González JF
    Clin Sci (Lond); 2009 Mar; 116(6):479-92. PubMed ID: 19200057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Research progress in signalling pathway in diabetic nephropathy.
    Ni WJ; Tang LQ; Wei W
    Diabetes Metab Res Rev; 2015 Mar; 31(3):221-33. PubMed ID: 24898554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reno-protective effect of NECA in diabetic nephropathy: implication of IL-18 and ICAM-1.
    Elsherbiny NM; Abd El Galil KH; Gabr MM; Al-Gayyar MM; Eissa LA; El-Shishtawy MM
    Eur Cytokine Netw; 2012; 23(3):78-86. PubMed ID: 22995127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of inflammatory cytokines in diabetic nephropathy.
    Navarro-González JF; Mora-Fernández C
    J Am Soc Nephrol; 2008 Mar; 19(3):433-42. PubMed ID: 18256353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renoprotective effect of berberine on type 2 diabetic nephropathy in rats.
    Sun SF; Zhao TT; Zhang HJ; Huang XR; Zhang WK; Zhang L; Yan MH; Dong X; Wang H; Wen YM; Pan XP; Lan HY; Li P
    Clin Exp Pharmacol Physiol; 2015 Jun; 42(6):662-70. PubMed ID: 25867602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NOD2 promotes renal injury by exacerbating inflammation and podocyte insulin resistance in diabetic nephropathy.
    Du P; Fan B; Han H; Zhen J; Shang J; Wang X; Li X; Shi W; Tang W; Bao C; Wang Z; Zhang Y; Zhang B; Wei X; Yi F
    Kidney Int; 2013 Aug; 84(2):265-76. PubMed ID: 23594678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammation in diabetic nephropathy.
    Lim AK; Tesch GH
    Mediators Inflamm; 2012; 2012():146154. PubMed ID: 22969168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetic nephropathy - is this an immune disorder?
    Tesch GH
    Clin Sci (Lond); 2017 Aug; 131(16):2183-2199. PubMed ID: 28760771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapies in diabetic nephropathy: an update.
    Gupta A; Gupta P; Biyani M
    J Nephrol; 2011; 24(6):686-95. PubMed ID: 22058027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.